Lis Ohlsson
Overview
Explore the profile of Lis Ohlsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
108
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vakil N, Wernersson B, Ohlsson L, Dent J
United European Gastroenterol J
. 2014 Nov;
2(3):173-8.
PMID: 25360300
Background: Symptomatically 'silent' gastro-oesophageal reflux disease (GORD) may be underdiagnosed. Objective: To determine the prevalence of untreated GORD without heartburn and/or regurgitation in primary care. Methods: Patients were included if...
2.
Vakil N, Halling K, Ohlsson L, Wernersson B
Am J Gastroenterol
. 2013 Apr;
108(5):767-74.
PMID: 23567354
Objectives: The Rome III criteria for functional dyspepsia recognize two distinct subgroups: postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS). The aim of this exploratory analysis was to evaluate...
3.
Ghali J, Wikstrand J, Van Veldhuisen D, Fagerberg B, Goldstein S, Hjalmarson A, et al.
J Card Fail
. 2009 Apr;
15(4):310-8.
PMID: 19398079
Background: Limited information is available on the risk and impact of renal dysfunction on the response to beta-blockade and mode of death in systolic heart failure (HF). Methods And Results:...
4.
Ersdal E, Schutzer K, Lonnerstedt C, Ohlsson L, Wall U, Eriksson U
Clin Drug Investig
. 2007 May;
25(7):425-33.
PMID: 17532684
Objective: To assess the potential effects of food on the pharmacokinetics and tolerability/safety of ximelagatran, an oral direct thrombin inhibitor developed for the prevention and treatment of thromboembolic disease that...
5.
Dorani H, Schutzer K, Sarich T, Wall U, Logren U, Ohlsson L, et al.
Eur J Clin Pharmacol
. 2007 Mar;
63(6):571-81.
PMID: 17387462
Objective: To study the effects of amoxicillin, doxycycline, ciprofloxacin, azithromycin, and cefuroxime on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, which...
6.
Van Veldhuisen D, Aass H, El Allaf D, Dunselman P, Gullestad L, Halinen M, et al.
Eur J Heart Fail
. 2006 Mar;
8(5):539-46.
PMID: 16567126
Background: Atrial fibrillation is common in heart failure, but data regarding beta-blockade in these patients and its ability to prevent new occurrence of atrial fibrillation are scarce. Methods: Baseline ECGs...
7.
Johansson S, Ohlsson L, Stenhoff H, Wahlander K, Cullberg M
Biopharm Drug Dispos
. 2005 Mar;
26(3):121-7.
PMID: 15751004
Background: In double-blind comparator studies with the oral direct thrombin inhibitor (oral DTI) ximelagatran, warfarin (Coumadin) was administered in encapsulated form in order to maintain patient and investigator blinding. This...
8.
Sarich T, Schutzer K, Dorani H, Wall U, Kalies I, Ohlsson L, et al.
J Clin Pharmacol
. 2004 Aug;
44(8):928-34.
PMID: 15286097
In this randomized, 2-way crossover study, the potential for interaction was investigated between atorvastatin and ximelagatran, an oral direct thrombin inhibitor. Healthy female and male volunteers (n = 16) received...
9.
Schutzer K, Wall U, Lonnerstedt C, Ohlsson L, Teng R, Sarich T, et al.
Curr Med Res Opin
. 2004 Mar;
20(3):325-31.
PMID: 15025841
Objective: To investigate whether crushed or dissolved tablets of the oral direct thrombin inhibitor ximelagatran are bioequivalent to whole tablet administration. Ximelagatran is currently under development for the prevention and...
10.
Johansson S, Wahlander K, Larson G, Ohlsson L, Larsson M, Eriksson U
Blood Coagul Fibrinolysis
. 2003 Oct;
14(7):677-84.
PMID: 14517494
The pharmacokinetic dose linearity and reproducibility, the effects on ex-vivo coagulation time assays and bleeding time, and tolerability of the direct thrombin inhibitor melagatran following subcutaneous (s.c.) dosing were investigated...